8592 Background: Variation in baseline host immune status contributes to inconsistent donor engraftment and may impede maximal graft-versus-myeloma effects after reduced intensity allogenic hematopoietic stem cell transplantation (RIHSCT) for advanced multiple myeloma (MM). As no specific salvage regimen has been designed for MM patients being considered for RIHSCT, we evaluated EPOCH-F a novel salvage regimen designed to provide disease control and immune depletion. Methods: EPOCH-F is an infusional chemotherapeutic regimen consisting of etoposide, vincristine and adriamycin, with prednisone, cyclophosphamide and fludarabine given in 21 day cycles prior to RIHSCT. Targeting a CD4+ T cell count, 22 pts were treated <5 cycles of EPOCH-F. Pts proceeded to RIHSCT after adequate lymphodepletion or if there was disease progression during EPOCH-F, regardless of CD4 count. Results: Median age was 53 years (range 36–65); median time from initial therapy to transplant was 12 months (range 2–168). Median number of prior therapies was 2 (range 1–8), 63% had chemotherapy sensitive disease and 68% had received a novel agent. Pts received a median of 3 cycles (range 1–5), with manageable toxicities, mostly hematologic. Grade IV Neutropenia was seen in 77% of the administered cycles with only 6 episodes of neutropenic fever. Median lymphocyte count decreased from 1423/μL (range 335–2788) to 519/μL (range 102–1420); CD4 count decreased from 320/μL (range 130–1366) to 115/μL (30–309). In 21 evaluable pts, the ≥PR rate to EPOCH-F was 22% with 13% CR/nCR. 68% had SD and only 1 pt progressed. 20 pts underwent RIHSCT from HLA matched sibling. Median Day 100 chimerism was 100% (range 60–100, mean 95). 70% of patients achieved ≥VGPR and CR/nCR was seen in 40%. Acute GVHD (grade II-IV) was seen in 47% and chronic GVHD (grade III-IV) was seen in 52% of the pts. TRM at 100 days was 5% and 30% at 60 months. Median overall survival of patients after RIHSCT was 46.1 months. Conclusions: EPOCH-F is an active regimen which provides pre-transplantation lympho-depletion, disease control and allows consistent engraftment in multiple myeloma patients undergoing RIHSCT. No significant financial relationships to disclose.